Agenus (AGEN) Raised to “Sell” at BidaskClub

Agenus (NASDAQ:AGEN) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Friday.

Other analysts have also recently issued reports about the company. Zacks Investment Research upgraded Agenus from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Wednesday, October 25th. ValuEngine cut Agenus from a “sell” rating to a “strong sell” rating in a research report on Friday, December 29th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $5.81.

Shares of Agenus (AGEN) opened at $3.65 on Friday. Agenus has a 1 year low of $3.20 and a 1 year high of $5.45. The company has a debt-to-equity ratio of -2.39, a current ratio of 1.55 and a quick ratio of 1.55.

In other news, insider Karen Valentine sold 8,358 shares of Agenus stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $3.46, for a total transaction of $28,918.68. Following the transaction, the insider now directly owns 109,879 shares in the company, valued at approximately $380,181.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 20,514 shares of company stock worth $70,978. 7.60% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Agenus by 1.2% during the 4th quarter. BlackRock Inc. now owns 4,883,221 shares of the biotechnology company’s stock valued at $15,920,000 after purchasing an additional 55,759 shares during the period. Vanguard Group Inc. increased its position in shares of Agenus by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after purchasing an additional 174,162 shares during the period. Artal Group S.A. increased its position in shares of Agenus by 25.0% during the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after purchasing an additional 500,000 shares during the period. Northern Trust Corp increased its position in shares of Agenus by 4.1% during the 2nd quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock valued at $3,682,000 after purchasing an additional 37,239 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its position in shares of Agenus by 6.0% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 655,000 shares of the biotechnology company’s stock valued at $2,135,000 after purchasing an additional 37,300 shares during the period. Institutional investors own 37.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/11/agenus-agen-raised-to-sell-at-bidaskclub.html.

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply